Compare AbCellera Biologics Inc (ABCL) vs iShares TIPS Bond ETF (TIP) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

TIP trades at $108.49 with minimal daily movement (+0.15%). Technical indicators show a bearish trend with moving averages signaling strong selling pressure, though oscillators remain neutral. The stock faces resistance at $109 with support at $108. Recent dividend announcements for 2026 provide income visibility, but key financial ratios are unavailable for fundamental assessment.

The outlook remains cautious due to bearish technical signals and lack of fundamental data. Dividend payments offer some stability, but investors need updated financial metrics to assess valuation. Market sentiment reflects broader bond market uncertainties and Federal Reserve policy concerns affecting income-focused equities.